


## COMPANY PROFILE


STRATEC SE (Frankfurt: SBS; Prime Standard, ISIN: DE000STRA555) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers integrated laboratory software and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain - from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

## SHARE CHART



Volume ■ Quotes increased ■ Quotes decreased



## SHAREHOLDER STRUCTURE

Investor group	Share
Fixed and family ownership (incl. investment companies)	40.36%
Treasury shares	0.02%
Free float	59.62%
Total	100.00%

## MANAGEMENT BOARD



Marcus  
Wolfinger

Dr. Robert  
Siegle

Dr. Claus  
Vielsack

Dr. Georg  
Bauer

## SUPERVISORY BOARD

› Prof. Dr. Georg Heni  
› Dr. Rolf Vornhagen

› Dr. Frank Hiller  
› Dr. Patricia Geller

## STOCK FUNDAMENTALS

ISIN	DE000STRA555
WKN	STRA55
Symbol	SBS
Reuters Code	SBSG.DE
Branch	Pharma & Healthcare
Transparency level	Prime Standard
Market segment	Regulated Market
Type of shares	Registered Shares
Registered capital	12,157,841 Euro
No. of shares	12.157.841
Initial listing	Aug 25, 1998
Stock exchanges	Xetra; Frankfurt am Main and other regional exchanges in Germany

## FINANCIAL CALENDAR

<b>Apr 26, 2024</b>	Publication quarterly statement (call-date Q1)
<b>May 14, 2024</b>	Pan European Small and Mid-Cap Conference Organized by: UBS
<b>May 15, 2024</b>	Berenberg Diagnostics Conference Organized by: Berenberg Bank
<b>May 17, 2024</b>	Annual General Meeting
<b>Jun 07, 2024</b>	Warburg Highlights Conference Organized by: Warburg Research
<b>Aug 09, 2024</b>	Publication half-yearly financial report
<b>Sep 04 - Sep 05, 2024</b>	21st Annual Goldman Sachs European Medtech and Healthcare Conference Organized by: Goldman Sachs
<b>Sep 25, 2024</b>	13th German Corporate Conference Organized by: Berenberg & Goldman Sachs
<b>Oct 25, 2024</b>	Publication quarterly statement (call-date Q3)
<b>Nov 18 - Nov 20, 2024</b>	7th MidCap CEO Conference Organized by: BNP Paribas Exane
<b>Nov 26, 2024</b>	German Equity Forum Organized by: Deutsche Börse - Analysts' Conference -

## KEY FIGURES AT A GLANCE

IFRS (in € million)	2019	2020	2021	2022	2023
Sales	214.2	250.1	287.3	274.6	261.9
Adjusted EBIT <sup>1</sup>	29.3	41.7	54.3	45.1	27.1
Adjusted EBIT margin (%) <sup>1</sup>	13.7	16.7	18.9	16.4	10.3
Adjusted consolidated net income <sup>1</sup>	24.1	35.2	45.1	34.7	16.7
Adjusted earnings per share (€) <sup>1</sup>	2.01	2.92	3.73	2.86	1.37
Dividend per share (€)	0.84	0.90	0.95	0.97	0,55 <sup>2</sup>
No. of employees	1,302	1,319	1,398	1,481	1,522
Total assets	299.4	331.9	368.5	397.5	466.6
Equity ratio (%)	53.1	52.0	55.8	56.6	50.0

<sup>1</sup>For comparison purposes, adjusted figures for 2023 have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses). In the previous year, earnings figures were additionally adjusted to exclude a provision for expected back payments of tax (including interest payments).

<sup>2</sup>Subject to approval by the Annual General Meeting on May 17, 2024.

**STRATEC SE**

Gewerbestr. 37  
75217 Birkenfeld  
Deutschland

Phone: +49 (0)7082 7916 0  
Fax: +49 (0)7082 7916 999  
info@strattec.com  
www.strattec.com

**Investor Relations**

Phone: +49 7082 7916-6515  
Fax: +49 7082 7916-9190  
ir@strattec.com